Caveolin-1 Expression and Hemodynamics in COPD Patients by Huber, L C et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2009
Caveolin-1 Expression and Hemodynamics in COPD Patients
Huber, L C; Soltermann, A; Fischler, M; Gay, S; Weder, W; Russi, E W; Speich, R; Ulrich, S
Abstract: Caveolin-1 is a regulator of both intracellular calcium homeostasis and endothelial nitric oxide
synthase and may play a pathogenetic role in pulmonary hypertension. In the present study, we aimed to
investigate the correlations between pulmonary hemodynamics and vessel morphology including the ex-
pression of Caveolin-1 in pulmonary arterioles from patients with chronic obstructive pulmonary disease
(COPD) who underwent lung-volume reduction surgery. Staining and subsequent analysis was performed
on paraffin-embedded lung tissue from COPD patients (n = 12). Pulmonary arteries with an external
diameter of 100-500microm were analysed. Immunhistochemistry with antibodies against caveolin-1 was
performed and intensity was assessed. Morphometric data were obtained by using computer-assisted
imaging software. The findings were quantified and correlated to hemodynamic data obtained by right-
heart catheterization. In COPD patients with pulmonary hypertension (n = 5), the expression of caveolin-
1 within the medial smooth muscle cell layer was found to be increased, whereas the intimal caveolin-1
was more prominently expressed in COPD patients with normal pulmonary pressures (n = 7). The ra-
tio between these expression patterns was positively correlated to the mean pulmonary artery pressure.
Similar findings were observed for the ratio between intimal and medial thickness as well as for the expres-
sion of smooth muscle actin (SMA).Taken together, the expression of caveolin-1 within medial smooth
muscle cells of pulmonary arteries in patients with COPD is associated with pulmonary hypertension.
Our results thus emphasize a potential novel player in the pathogenesis of COPD-associated pulmonary
hypertension.
DOI: 10.2174/1874306400903010073
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-27417
Originally published at:
Huber, L C; Soltermann, A; Fischler, M; Gay, S; Weder, W; Russi, E W; Speich, R; Ulrich, S (2009).
Caveolin-1 Expression and Hemodynamics in COPD Patients. Open Respiratory Medicine Journal, 3:73-
78. DOI: 10.2174/1874306400903010073
Caveolin-1 Expression and Hemodynamics in COPD patients  
 
Running title: Caveolin-1 and pulmonary hemodynamics in COPD 
 
Key Words: caveolin-1, chronic obstructive pulmonary disease (COPD), morphometry, 
pulmonary hypertension  
 
Abstract 
 
Caveolin-1 is a regulator of both intracellular calcium homeostasis and endothelial nitric 
oxide synthase and may play a pathogenetic role in pulmonary hypertension. In the present 
study, we aimed to investigate the correlations between pulmonary hemodynamics and vessel 
morphology including the expression of Caveolin-1 in pulmonary arterioles from patients 
with chronic obstructive pulmonary disease (COPD) who underwent lung-volume reduction 
surgery. Staining and subsequent analysis was performed on paraffin-embedded lung tissue 
from COPD patients (n=12). Pulmonary arteries with an external diameter of 100-500m 
were analysed. Immunhistochemistry with antibodies against caveolin-1 was performed and 
intensity was assessed. Morphometric data were obtained by using computer-assisted imaging 
software. The findings were quantified and correlated to hemodynamic data obtained by right-
heart catheterization. In COPD patients with pulmonary hypertension (n=5), the expression of 
caveolin-1 within the medial smooth muscle cell layer was found to be increased, whereas the 
intimal caveolin-1 was more prominently expressed in COPD patients with normal pulmonary 
pressures (n=7). The ratio between these expression patterns was positively correlated to the 
mean pulmonary artery pressure. Similar findings were observed for the ratio between intimal 
and medial thickness as well as for the expression of smooth muscle actin (SMA). 
Taken together, the expression of caveolin-1 within medial smooth muscle cells of pulmonary 
arteries in patients with COPD is associated with pulmonary hypertension. Our results thus 
emphasize a potential novel player in the pathogenesis of COPD-associated pulmonary 
hypertension. 
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Background 
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in 
industrialized countries [1]. One factor contributing to the devastating outcome of end-stage 
COPD is the development of pulmonary hypertension and cor pulmonale. In cross-sectional 
studies, pulmonary hypertension and right heart failure have been found in more than 10% of 
patients dying from COPD [2, 3]. The arterial vessels in idiopathic pulmonary hypertension 
are characterized by intense thickening of their walls through fibromuscular proliferation and 
microthrombotic occlusion [4, 5], whereas in the setting of COPD, vasoconstriction induced 
by hypoxia may play a pivotal role. In either case, the molecular factors mediating the 
vascular changes that increase pulmonary vascular resistance in COPD patients remain largely 
unravelled so far. Recently however, the role of caveolins (Cav) as emerging signalling 
molecule has been investigated in animal models of pulmonary hypertension as well as in 
lung tissue samples from patients with idiopathic pulmonary arterial hypertension [6-9]. Cav-
1 is a 22kDa protein located in cholesterol- and glycosphingolipid enriched microdomains 
(lipid rafts or caveolae) that act as chaperons and scaffolding regions in order to anchor and 
regulate proteins [7, 10, 11]. In this regard, Cav-1 is involved in the regulation of many 
cellular processes including signal transduction and calcium homeostasis [12]. Moreover, a 
strong relationship between Cav-1 and endothelial nitric oxide-synthase (eNOS) has been 
described (reviewed in [13]) and binding of eNOS to Cav-1 appears to inhibit the enzymatic 
function [14]. Both, changes in the intracellular calcium-storage resulting in increased 
vascular tone and a reduction in the production and release of endothelial NO, have been 
associated with the pathogenesis of pulmonary hypertension. The knockout of the cav-1 gene 
in mice resulted in lung fibrosis and subsequent development of cor pulmonale [9, 15]. 
Conversely, a recent study by Patel has found an increased expression of Cav-1 in smooth 
muscle but not in endothelial cells in pulmonary arteries from patients with idiopathic 
pulmonary arterial hypertension [7].  
Along this line, we investigated the vessel morphology and expression of Cav-1 in small 
pulmonary arteries from COPD patients that underwent lung-volume reduction surgery 
(LVRS). 
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Methods and Materials 
 
Patients/ Tissue sections 
Paraffin-embedded lung tissue sections were obtained from COPD patients undergoing lung 
volume reduction surgery or lung transplantation. Pulmonary hemodynamics was assessed by 
right-heart catheterization performed before surgery. Patients with a mean pulmonary arterial 
pressure (mPAP) ≤ 20mmHg were chosen as controls (n=7), whereas patients with a mPAP ≥ 
25mmHg were considered to have pulmonary hypertension (n=5). The experimental use of 
these data was approved by an internal review board of the local Ethics committee of Zurich. 
In addition, all patients gave written informed consent for further experimental analysis of 
their explanted tissue and clinical data. Details of patients’ characteristics are provided in 
Table 1.  
 
 
Immunohistochemistry 
Serial sections of 2m were manufactured from tissue blocks and were stained with 
hematoxylin eosin (HE) and Elastica van Gieson (EVG). Immunhistochemistry was 
performed on a Ventana automat (Ventana Medical Systems) with antibodies directed against 
Cav-1 (BD Transduction Laboratories, mouse monoclonal, clone 2297, 1:100) and smooth 
muscle actin (-SMA) prior to analysis by light microscopy. For analysis, staining was 
assessed on 3 vessels/slide in a semiquantitative manner by using a visual scoring system (0 = 
no staining, 1 = weak, 2 = moderate, 3 = strong).  
 
 
Morphometry 
Morphometry data were obtained by using computer-assisted imaging software (Axiovision, 
Zeiss). Pulmonary arteries with an external diameter of 100-500m were randomly chosen 
followed by analysis (n=7 per slide and individual patient). Only vessels with a cross-
sectional morphology were chosen to minimize artificial effects by longitudinal or tangential 
cuts. Additionally, tissue shrinkage was corrected by calculation of a narrowing index. The 
adventitial layer, the external and internal elastic laminas (EEL and IEL, respectively) 
encompassing the vessel’s smooth muscle cell layer (medial layer) as well as the intimal layer 
were outlined manually at the screen. The perimeter and the corresponding diameter were 
calculated automatically by the imaging software. Moreover, the diameter was corrected by a 
narrowing index to avoid artificial vascular contraction due to tissue shrinkage [16]. Thus, the 
measured perimeter was divided by  to calculate a theoretical diameter of a fully extended 
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vessel. Lumen as well as intimal, medial and adventitial layer areas were calculated and 
expressed as percentage of the whole vessel area. The final data per patient was expressed as 
mean of all vessels analysed. 
 
Statistics 
For statistical analysis, the unpaired t-test was used to compare data from the two groups. 
Correlation analyses (correlation coefficient Pearson r) were performed to assess correlations 
between pulmonary hemodynamics, thickness of vessel layers and immunohistochemical 
expression of distinct proteins. Statistics were performed using GraphPad Prism Software 
system (GraphPad Software, San Diego, CA, USA) and a p value <0.05 was considered to be 
statistically significant. All data are shown as mean ± SD. 
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Results 
 
Vessel morphometry  
As shown in Table 2, a total of 7 vessels were investigated for each individual patient with 
similar mean diameters of 223.6 ± 87.4 m for COPD patients with pulmonary hypertension 
and of 292 ± 88 m for COPD patients without pulmonary hypertension, respectively. The 
intimal layer area was found to be strongly reduced from 40.8 ± 16.8% in patients without 
pulmonary hypertension to 31.7 ± 16.3% in patients with pulmonary hypertension. No 
significant changes have been observed in the thickness of the smooth muscle cell area 
between the two groups. The thickness of the adventitial area on the other hand, was 
significantly increased in patients with pulmonary hypertension from 27 ± 19% to 40.4 ± 
16.4%, respectively (p=0.05).  
When analysed by subsequent linear regression analysis (Fig. 1), the ratio between the intimal 
and the medial vessel layer was positively correlated to the mean pulmonary arterial pressure 
(r2=0.49). Similarly, the thickness of the adventitial layer expressed as percentage of the 
whole vessel was strongly correlated to the mPAP (r2=0.67).  
 
 
 
Caveolin-1 expression 
By using a visual scoring system, immunohistochemical stainings of pulmonary arteries were 
assessed in a semiquantitative manner (Fig. 2). The expression of Cav-1 within the smooth 
muscle cell layer was found to be increased in COPD patients with pulmonary hypertension 
as compared to the individuals without pulmonary hypertension (1.78 ± 0.73 versus 1.29 ± 
0.5). On the other hand, the intimal Cav-1 was most prominently expressed in COPD patients 
without pulmonary hypertension (2.6 ± 0.37), but appeared to be reduced in patients with 
pulmonary hypertension (2.34 ± 0.52). Figure 3 shows representative images of the Cav-1 
expression pattern in pulmonary arteries of COPD patients with and without pulmonary 
hypertension.  
Subsequent correlation analysis found a strong positive association between the mPAP and 
the Cav-1 expression pattern when expressed as ratio between medial and intimal Cav-1 
(r2=0.53, p=0.007) as shown in Figure 1b. A similar relationship was detected between the 
expression of -SMA in the intimal and medial layer and the corresponding mPAP (Fig. 1c).  
 
 5
Discussion 
 
Caveolins have emerged as novel signalling molecules acting as signal transducers and 
mediators of calcium homeostasis. The isoform Cav-1 has been particularly investigated in 
animal models of pulmonary hypertension and, by one pilot study, in human tissue samples 
derived from patients with idiopathic pulmonary arterial hypertension [6-9].   
 
Our investigation of the vessel morphometry and the Cav-1 expression in small pulmonary 
arteries derived from COPD patients with and without concomitant pulmonary hypertension 
showed a reduction of the Cav-1 expression in the intimal layer of the vessels in patients with 
pulmonary hypertension. Conversely, the Cav-1 expression in the smooth muscle cell layer 
was found to be increased in COPD patients with pulmonary hypertension. The ratio of either 
trend, assessed in a semiquantatitive manner at the light microscopy, was associated with 
rising pulmonary arterial pressure. Since similar changes were also observed in the expression 
pattern of an independent smooth muscle cell marker (i.e. -SMA), it might be suggested that 
the Cav-1 expression is strongly linked to the vascular distribution of smooth muscle cells. 
 
In pulmonary hypertension, the weak expression of Cav-1 in the intimal layer might be due to 
an accelerated loss of caveolar peptides through a disrupted and dysfunctional endothelium. 
Since the bone morphogenetic protein receptor type II (BMPR2), one of the pathogenetic key 
molecules involved in the development of pulmonary hypertension, co-localizes with 
caveolins [17], the loss of Cav-1 might also be explained by the downregulation of the 
BMPR2 at the endothelial surface of pulmonary arteries as it has been described repeatedly in 
pulmonary hypertension. The elevated vascular resistance in pulmonary hypertension is 
mediated by calcium ions that promote the contraction of smooth muscle cells on the 
molecular level. The weak expression of Cav-1 in the intimal area of pulmonary arteries thus 
could alternatively be explained by an enhanced transcytosis of calcium by [Ca2+]-influx 
channels and ion pumps located on caveolar domains through the endothelium to the smooth 
muscle cell layer. Conversely, the high expression of Cav-1 observed within the vascular 
smooth muscle cells in COPD patients with pulmonary hypertension is probably related to 
increased levels of sarcoplasmic [Ca2+] due to highly active transient receptor potential 
channels. It is unclear at the moment, whether the abundant expression of Cav-1 within 
vascular smooth muscle cells is directly connected to the upregulation of other important 
signalling molecules in COPD patients with pulmonary hypertension. However, several 
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molecules with pathogenetic relevance for the development of pulmonary hypertension have 
been located on caveolins including epidermal growth factor (EGF), platelet-derived growth 
factor (PDGF), receptors for endothelin and serotonine transporters [8, 18-23]. Our data thus 
support the hypothesis that caveolins are involved in the regulation and expression of these 
factors and, in turn, are of pathogenetic importance for the development of pulmonary 
hypertension.  
 
The clinical relevance of our findings, on the other hand, is less clear and has to be addressed 
by further studies. Since novel therapies directed against some of the molecules mentioned 
above have already been approved for the treatment of pulmonary hypertension, or, at least, 
are currently under investigation in clinical trials, we believe that caveolins might offer an 
interesting molecular target for novel therapeutic strategies as well. Along this line, HMG-
CoA-reductase inhibitors (statins) were shown to alter the distribution pattern of the 
cholesterol-enriched caveolins [7] and their application has been shown to ameliorate 
pulmonary hypertension in several animal models [24, 25].  
 
The “classical” morphological features of pulmonary hypertension such as the formation of a 
neo-intima and marked hyperproliferation of the smooth muscle cell layer have not been 
observed in the present study. This might be due to the fact that the increase in pulmonary 
vascular resistance in COPD-related pulmonary hypertension is generally very moderate. Our 
study is further limited by the lack of a control group consisting of patients without COPD 
and the relatively small number of patients. Nevertheless, the findings presented herein are in 
line with the data from Patel et al, and therefore strongly suggest a common molecular 
pathway involving caveolar proteins in the development of pulmonary hypertension both in 
its idiopathic form and in relation with advanced COPD.  
 
In summary, we show for the first time that the expression pattern of Cav-1 within pulmonary 
arteries is associated with pulmonary hypertension in COPD patients. Consistent with the 
results from studies performed in tissue samples derived from idiopathic pulmonary arterial 
hypertension, the expression of Cav-1 was found to be correlated with the pulmonary arterial 
pressure. Since caveolin has been associated with different molecular players in pulmonary 
hypertension and, moreover, appears to regulate fibrosis a least in part, our results emphasize 
a potential novel factor in the pathogenesis of COPD-associated pulmonary hypertension.   
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Figure legends 
 
Figure 1: Correlation analyses. 
A) Parametric analyses to calculate the Pearson r correlation coefficient showed strong 
associations between pulmonary hemodynamics (mPAP) and the ratio between the thickness 
of medial and intimal vessel areas (r2=0.49). B) Significant correlation were also found 
between mPAP and the ratio between medial : intimal Cav-1 expression (r2=0.53, p=0.007). 
C) A similar correlation was found between mPAP and the ratio between medial : intimal -
SMA expression (r2=0.48). 
 
 
Figure 2: Cross-sectional imaging studies of a pulmonary artery (IHC) 
Serial stainings performed at lung tissue slides derived from an index patient without 
pulmonary hypertension: A) Hematoxylin-Eosin (HE) and B) Elastin-van Gieson (EVG).   
 
Figure 3: Cav-1 expression pattern in COPD patients with and without pulmonary 
hypertension 
A) Cav-1 was found strongly expressed within the media of pulmonary arteries derived from 
COPD patients with pulmonary hypertension as compared to their counterparts without 
pulmonary hypertension (C). Conversely, the intimal expression of Cav-1 was increased in 
patients without and decreased in patients with high pulmonary pressure. Serial stainings for 
-SMA are shown in B and D, respectively. 
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 Table 1: Characteristics of analysed patients.  
 
 COPD with PH (n=5) COPD without PH (n=7) 
age 56±11.9 [42-72] 67±9.0 [54-79] 
gender (m:f) 2:3 4:3 
ethnic group Caucasian Caucasian 
mPAP (mmHg) 29.6±5.1 [38-26] 16.7±2.7 [20-12] 
spirometric data 
- FVC (% predicted) 
- FEV1 (% predicted) 
 
59±19.8 
26±7.3 
 
59±12.9 
27±5.8 
SaO2 (%) 89±5.2 94±3.9 
smoking status 
- pack years 
5/5 
62±53.1 [10-150] 
7/7 
61±22.3 [35-100] 
   
 
abbreviations used: FVC forced vital capacity, FEV1 forced expiratory volume in one second, 
SaO2 oxygen saturation in arterial blood  
 
 
Table 2: Vessel morphometry. 
 
 COPD with PH 
(n=5) 
COPD without PH 
(n=7) 
vessels analysed/ slide 7 7 
diameter of pulmonary artery (m)¶ 223.1±85.9 [110-419] 292±88 [125-465] 
diameter of EEL (m) ¶ 193.6±83.6 265.6±80.6 
diameter of IEL (m) ¶ 169.8±75.4 233.3±76.6 
intimal area (mm2) 
- % of total vessel area 
10.0±10.7 
31.7±16.3 
16.4±13.5 
40.8±16.8 
media area (mm2) 
- % of total vessel area 
7.9±6.9 
27.3±11.1 
13.1±12.2 
32.1±17.6 
adventitial area (mm2) 
- % of total vessel area 
10.0±6.6 
40.4±16.4 
12.6±13.2 
27±19 
Caveolin expression 
- intimal caveolin 
- medial caveolin 
 
2.34±0.52 
1.78±0.73 
 
2.60±0.37 
1.29±0.5 
   
 
¶ Narrowing index applied  
(theoretical diameter was calculated by dividing the measured perimeter by ) 
 
EEL = external elastic layer  
IEL = internal elastic layer 
 
 
 
 
